PIC/S Committee has Adopted a Guide on Good Distribution Practice
The PIC/S Committee has adopted a Guide on Good Distribution Practice (GDP), which will enter into force on 1st June 2014. The PIC/S GDP Guide is based on the EU GDP Guide.
The PIC/S GDP Guide is a non-binding guidance document because PIC/S is not a regulatory authority in the sense of the competent authorities in the EU and the regulatory authorities in the US, Canada, Australia and Japan.
Each of the competent authority PIC/S members will make the decision regarding whether the guideline is to be implemented and enforced. Several regulatory authorities outside of the EU are members of PIC/S including the US, Canada, Japan and Australia. How this will be applied by those authorities is unknown at this time.
While the PIC/S guideline is based upon the EU GDP Guide and Chapters 1 through 9 have the same structure as the EU guideline, the following differences are noted with regard to the PIC/S GDP Guideline:
• EU specific references have been removed
• Import activities are included
• “Responsible Person” is replaced by designated responsible person(s)
• Contains more references to risk management throughout
• Additional reference are made to record(s)/procedure(s)s that should be maintained
• Batch/expiry guidance is based upon national legislation
• Contains more general requirements for import/export (not EU specific)
Includes more detail on actions taken upon identification of falsified medicines, including recall guidelines
• Does not contain a chapter on Brokers as in the EU Guide
• Lists additional glossary terms; including temperature, with defined ranges.
To view or download the PIC/S GDP Guidance, click here
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance